Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer that expresses myogenic
master regulatory factor MYOD but fails to differentiate. Here, we show that the zinc finger …

Relapsed pediatric rhabdomyosarcomas (RMS) and neuroblastomas (NBs) have a poor
prognosis despite multimodality therapy. In addition, the current standard of care for these …

Simple Summary The prognosis for patients with relapsed neuroblastoma is poor, and novel
treatment options for these patients are needed. Some relapsed neuroblastoma tumors …

Background Enhanced Recovery After Surgery (ERAS) protocols for bariatric surgery
improve clinical outcomes. However, the impact of ERAS protocols on patient satisfaction is …

Background: In an aging surgical patient population, preventing complications such as
oversedation has taken increasing priority in perioperative care. Intraoperative use of Virtual …

The RASopathies are a group of disorders caused by a germline mutation in one of the
genes encoding a component of the RAS/MAPK pathway. These disorders, including …

RASopathies caused by germline pathogenic variants in genes that encode RAS pathway
proteins. These disorders include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), …

Human acute myeloid leukemia (AML), the most common type of acute leukemia, has
approximately eight subtypes, many of which have poor prognosis. Most of these subtypes are …

Directly targeting RAS is a desirable approach for treating RAS-mutated tumors because direct
RAS inhibitors block all RAS effector pathways simultaneously. Recently, several groups …

Thanks to the efforts of our reviewers in 2022, the median time to first decision was 15 days
and the median time to publication was 36 days. I Electronics i was able to uphold its high …